Nanobiotix Phase 1 Study of JNJ-1900 (NBTXR3) for Pancreatic Cancer Yields Results
Full results from Nanobiotix's Phase 1 study evaluating JNJ-1900 (NBTXR3) for locally advanced or borderline resectable pancreatic cancer have been released. The study demonstrated favorable safety and encouraging oncologic outcomes.
Nanobiotix has announced full results from its completed Phase 1 study evaluating the nanotherapeutic JNJ-1900 (NBTXR3) in patients with locally advanced or borderline resectable pancreatic cancer. The study, conducted by The University of Texas MD Anderson Cancer Center, showed favorable safety, injectability, and encouraging outcomes in 22 patients.
The presented data reveals a median overall survival (OS) of 23 months from the date of diagnosis, a significant increase compared to historical controls at the same center. Additionally, a median local progression-free survival (LPFS) of 13.3 months from the completion of radiation therapy was observed.
Intriguing findings also emerged from exploratory biomarker analyses. The study identified an association between increased circulating tumor mutational burden (cTMB) and improved LPFS and OS. Furthermore, 59% of patients achieved normalization of CA19-9, a marker that correlated with extended survival.
According to Nanobiotix, these results support further evaluation in a randomized study. A new patient cohort has commenced, combining JNJ-1900 (NBTXR3) with standard-of-care concurrent chemotherapy (capecitabine or 5-FU) alongside radiation therapy.
The treatment of locally advanced or borderline resectable disease presents a significant unmet need, as current therapies rarely yield curative outcomes. The findings were presented at the 2025 Annual Meeting of the European Society for Radiotherapy and Oncology (ESTRO).